Enhancing facilitated transport has been of interest for several diseases, most prominently with cystic fibrosis transmembrane conductance regulator (CFTR) and cystic fibrosis but also with the glutamate transporters and amyotrophic lateral sclerosis [40,41,42]. This evidence concerns the gene CFTR and cystic fibrosis.